HLS Therapeutics Inc HLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 30.94M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.88%
Company Profile
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 86
- Website
- https://www.hlstherapeutics.com
Valuation
|
Metric
|
HLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.63 |
Price/Sales | 1.65 |
Price/Cash Flow | 6.74 |
Price/Earnings
HLS
Financial Strength
|
Metric
|
HLS
|
|---|---|
Quick Ratio | 0.76 |
Current Ratio | 1.05 |
Interest Coverage | −0.90 |
Quick Ratio
HLS
Profitability
|
Metric
|
HLS
|
|---|---|
Return on Assets (Normalized) | −5.32% |
Return on Equity (Normalized) | −12.02% |
Return on Invested Capital (Normalized) | −2.56% |
Return on Assets
HLS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|@H>&gfdf | LOCK|yGYD? | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|&k#S$V@ | LOCK|?Y?B | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|!S?$c? | LOCK|ns | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|M<MVgGx^ | LOCK|PVk | $33B | |||
| Viatris Inc
VTRS
| LOCK|$N@Lqb | LOCK|$%@ | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|!#% | LOCK|PS | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|<<#&@ys | LOCK|?mN | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|&!h!&Mx | LOCK|<P | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|LgPmJ? | LOCK|?Y^M | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|jZC>VyZ | LOCK|F$ | $2B |
United States